Oct. 24, 2025: State Advocacy Update

| 1 Min Read
Contents
  1. New issue brief provides kratom and tianeptine basics, AMA recommendations
  2. More articles in this issue

New issue brief provides kratom and tianeptine basics, AMA recommendations

A new issue brief (PDF) from the AMA Advocacy Resource Center provides key information about kratom and tianeptine—two unregulated substances that have generated increasing reports of public health harms. The issue brief includes basic information about the substances, including the fact that neither has been approved by the U.S. Food and Drug Administration.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update newsletter.

Sign Up/Create Account

The AMA recommends the safety and efficacy of kratom should be determined through research and clinical trials and subsequently evaluated by the relevant regulatory entities for its appropriateness for sale and potential oversight via the Controlled Substances Act, before it can be marketed, purchased or prescribed. The AMA also advocates to ban the sale of tianeptine directly to the public in the absence of research into the safety and efficacy of the substance. 

Your Powerful Ally

The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most—patients. We will meet this challenge together.

Join Us

FEATURED STORIES

Figures on a giant magnifying glass look at a document

Behind Oregon’s first-in-nation law curbing corporate medicine

| 5 Min Read
Smiling patient with doctor

CEOs push physician well-being from perk to performance goal

| 8 Min Read
Team of doctors discussing over x-ray report

8 health systems finding success in physician recruitment, retention

| 8 Min Read
Columns of the U.S. Supreme Court at top of steps

8 wins for doctors, patients in latest federal budget deal

| 4 Min Read